[Form 4] HeartBeam, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Willem Elfrink, a director of HeartBeam, Inc. (BEAT), reported transactions dated 07/11/2025 on a Form 4 filed for changes in beneficial ownership. The filing shows 106,825 shares held indirectly by the Elfrink Living Trust and a reported disposition of 351,167 shares of Common Stock. The reporting person received 60,483 restricted stock units (RSUs) on 07/11/2025, which vest 100% on the earlier of 07/11/2026 or the company's 2026 annual meeting if he remains an Outside Director. The filing also discloses stock options covering 45,454 shares with a stated exercise price of $1.65; the explanatory text references a grant on 09/30/2025 and vesting tied to a 07/01/2025 commencement date per the company’s 2022 Equity Incentive Plan. The Form is signed by Mr. Elfrink on 10/02/2025.

Positive

• 60,483 RSUs granted to the reporting director, vesting by 07/11/2026, aligning compensation with continued service
• 45,454 option shares issued at an exercise price of $1.65 under the 2022 Equity Incentive Plan, indicating retention incentives

Negative

• 351,167 shares disposed by the reporting person, a sizable transaction relative to reported holdings
• Ownership reduced to 106,825 indirect shares held in the Elfrink Living Trust following reported activity

Insights

Securities Compliance Analyst

Insider reported a large disposition plus equity grants tied to director service.

The Form 4 shows a disposition of 351,167 shares and indirect ownership of 106,825 shares via the Elfrink Living Trust; both items are explicitly disclosed on the form. This simultaneous large sale and new equity grants are both reportable events under Section 16 and are correctly documented with transaction and signature dates.

The filing also documents 60,483 RSUs that vest on the earlier of 07/11/2026 or the 2026 annual meeting, and options covering 45,454 shares at an exercise price of $1.65, with grant/vesting dates referenced. These equity awards are typical director compensation items and are material to holder dilution and insider alignment.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Elfrink Willem

(Last) (First) (Middle)

2118 WALSH AVE, SUITE 210

(Street)

SANTA CLARA CA 95050

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HeartBeam, Inc. [ BEAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								106,825	I(1)	See Footnote(1)
Common Stock								351,167	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Award	$0							(2)	(3)	Common Stock	60,483		60,483	D
Common Stock (right to buy)	$1.65							(4)	07/01/2035	Common Stock	45,454		89,090	D

Explanation of Responses:

1. These shares are held by the Elfrink Living Trust, of which the Reporting Person is the trustee.

2. These securities are restricted stock units (RSUs) granted on July 11, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. 100% of the RSUs shall vest on the earlier of July 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's 2022 Equity Inventive Plan) through the applicable vesting date.

3. RSUs do not expire, they either vest or are canceled prior to vesting date

4. Granted options on September 30, 2025, one half of the total number of Shares subject to the Special Option shall vest on the three-month anniversary of the vesting commencement date (July 1, 2025) and the remaining Shares shall vest on the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

Remarks:

	/s/ Willem Elfrink	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did HeartBeam director Willem Elfrink report on Form 4 (BEAT)?

The Form 4 reports a disposition of 351,167 shares, indirect ownership of 106,825 shares via the Elfrink Living Trust, 60,483 RSUs granted on 07/11/2025, and options for 45,454 shares at $1.65.

When do the RSUs granted to the director vest?

The 60,483 RSUs vest 100% on the earlier of 07/11/2026 or the Issuer's 2026 annual meeting, subject to the director remaining an Outside Director.

What is the exercise price and vesting reference for the options disclosed?

The disclosed options cover 45,454 shares with an exercise price of $1.65; the explanatory text references a grant on 09/30/2025 and vesting tied to a 07/01/2025 commencement schedule.

Who holds the indirect shares reported and in what form?

The 106,825 indirect shares are held by the Elfrink Living Trust, for which the reporting person is the trustee, as stated in the filing.

When was the Form 4 signed and filed?

The Form 4 is signed by Willem Elfrink on 10/02/2025, with the earliest transaction date on the form shown as 07/11/2025.